Philippe Dro joined GlycoVaxyn as Chief Executive Officer and member of the Board of Directors in April 2008. He has 20 years of experience in the life science industry, including pharma, biotech and med-tech companies.
Most recently, he was Chairman and CEO of Endoart, a med-tech company developing telemetric driven implants for cardiac diseases and obesity. Endoart was sold to Allergan. From 1999 to 2003, Dr. Dro was COO and part of the founding team of AXOVAN, a GPCR focused drug discovery company, where he helped to grow the company to become a clinical-stage entity, which was ultimately acquired by Actelion. Prior to this, he held the position of COO and he was also a member of the Board of Directors of Antares Pharma, a drug delivery company formed by the merger of Permatec Group and Mediject. He also held executive director positions at Skyepharma during its listing on the LSE and in finance at Sandoz Pharma (now Novartis).
Dr. Dro holds a PharmD from University of Grenoble (France) and an MBA jointly from Ecole Supérieure de Commerce de Lyon (France) and Cranfield School of Management (UK).